Healthcare: Medicine sales on the drop

The sale of medicines at distribution price dropped in Romania in the third quarter by 3.3% compared to the same period of 2012, to 2.7 billion lei, according to Cegedim Romania which showed that the availability of many products was significantly affected.

In euro, the market dropped by 1.6% to 627.6 million euro. “Recent results confirm difficulties in the pharmaceutical market. The prognosis is still modest with an annual growth rate of 0.7% in 2013, while for 2014 the previously announced prognosis (+2.7% in lei) might be adjusted at the end of the ongoing year,” said Petru Craciun, the general manager of Cegedim Romania.

At the level of the first 9 months, the total market value was 8.69 billion lei (1.97 billion euro, on the rise by 1.2% compared to the previous year, due to a better performance in the first semester. The rise was 1.8% in euro.

The hierarchy of the main 20 corporations in the last 12 months changes compared to the previous quarter because of the Abbott group separation (the appearance of two companies Abbott and Abbvie) and the exit of Gedeon Richter. Sanofi (including Zentiva) with sales of 873.2 million lei and a market share of 7.4% remained in the top, followed by Hoffmann La Roche with 862.6 million lei and a share of 7.3% and Novartis with 718.4 million lei and 6.1%.

The top of the first 10 players is completed by Servier (677 million lei and 5.7%), Pfizer (617.9 million and 5.2%), GlaxoSmithKline (563.3 million lei and 4.8%), Merck&Co (486.3 million lei and 4.1%), AstraZeneca (460.5 million lei and 3.9%), Ranbaxy (445/7 million lei and 3.8%) and Krka (308.2 million lei and 2.6%).

On positions 11-20 we find the companies Antibiotice, Johnson&Johnson, Teva, Abbvie, Menarini, Britstol Myers Squibb, Bayer, Alvogen, Abbott and Eli Lilly, their market shares varying between 1.6% and 2.5%.

Developed by Codecraftsman